| Revista: | Anais da Academia Brasileira de Ciencias |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000436072 |
| ISSN: | 0001-3765 |
| Autores: | Trindade, Guilherme G1 Caxito, Samyra M.C2 Xavier, Alessandra Rejane E.O3 Xavier, Mauro A.S3 Brandao, Fabiana4 |
| Instituciones: | 1Universidade de Brasilia, Laboratorio de Microbiologia Clinica e Imunologia, Brasilia, Distrito Federal. Brasil 2Instituto de Gestao Estrategica de Saude do Distrito Federal, Departamento de Enfermagem, Brasilia, Distrito Federal. Brasil 3Universidade Estadual de Montes Claros, Centro de Ciencias Biologicas e da Saude, Montes Claros, Minas Gerais. Brasil 4Universidade de Brasilia, Nucleo de Medicina Tropical, Brasilia, Distrito Federal. Brasil |
| Año: | 2020 |
| Volumen: | 92 |
| Número: | 2 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, prospectivo |
| Resumen en inglés | COVID-19 emerged in December 2019 in China, and since then, has disrupted global public health and changed economic paradigms. In dealing with the new Coronavirus, SARS-CoV-2, the world has not faced such extreme global fragility since the “Spanish flu” pandemic in 1918. Researchers globally are dedicating efforts to the search for an effective treatment for COVID-19. Drugs already used in a clinical setting for other pathologies have been tested as a new therapeutic approach against SARS-CoV-2, setting off a frenzy over the preliminary data of different studies. This work aims to compile and discuss the data published thus far. Despite the potential effects of some antivirals and antiparasitic against COVID-19, clinical studies must confirm real effectiveness. However, non-pharmacological approaches have proven to be the most efficient strategy to date |
| Disciplinas: | Medicina |
| Palabras clave: | Neumología, Terapéutica y rehabilitación, Farmacología, COVID-19, SARS-CoV-2, Antivirales, Antiparasitarios |
| Keyword: | Pneumology, Therapeutics and rehabilitation, Pharmacology, Antiviral agents, Antiparasitic agents, COVID-19, SARS-CoV-2 |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
